Overview

Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients

Status:
Completed
Trial end date:
2016-10-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn if the biomarker information obtained (learned or received) from the earlier studies can tell us whether or not Taxotere and/or Adriamycin/Cytoxan can cause tumors to become smaller.
Phase:
Phase 2
Details
Lead Sponsor:
Baylor Breast Care Center
Mothaffar Rimawi
Collaborator:
Baylor College of Medicine
Treatments:
Cyclophosphamide
Docetaxel
Doxorubicin
Liposomal doxorubicin